Introduction
Leading pharmaceutical player receives European Commission approval for AVT03, a proposed biosimilar of Prolia and Xgeva, supported by clinical evidence and enabled through an existing development and commercialization agreement.
Also Read: RVNL: Stock jumps on emerging L1 bidder for ₹180.77 Cr rail project
Share price movement of Dr. Reddy’s Lab
On November 25, 2025, Dr. Reddy’s Laboratories Ltd opened at ₹1,232.30, up 0.62% from its previous close of ₹1,224.75. The stock reached a high of ₹1,246.00 (1.74%) and a low of ₹1,231.85 (0.58%). By 11:15 AM, it traded at ₹1,237.80, a 1.07% increase, with a market cap of ₹1,03,304.58 crore.
Dr. Reddy’s Gets EC Nod for AVT03
Dr. Reddy’s Laboratories received European Commission approval for AVT03, a proposed biosimilar of Prolia and Xgeva. The authorization applies across the EU and EEA. The decision followed a positive CHMP opinion.
Prolia treats osteoporosis and bone loss in defined patient groups. Xgeva prevents bone complications in adults with advanced cancers and treats giant cell tumour of bone. The EC approval is supported by analytical, pharmacokinetic, pharmacodynamic and clinical data.
Dr. Reddy’s and Alvotech have a license and supply agreement for AVT03. Alvotech will develop and manufacture the biosimilar. Dr. Reddy’s will commercialize it as Acvybra and Xbonzy in applicable markets.
Stock performance of Dr. Reddy’s Lab for Period of 1 week, 6 months, and 1 year
Dr. Reddy’s Laboratories Ltd delivered a 1.42% return over the past week and reported a 1.76% return in the past six months. The stock posted a 1.40% gain over the past year.
Also Read: H.G. Infra: Stock jumps 6% after winning ₹1415 Cr metro rail projects
Shareholding pattern of Dr. Reddy’s Lab
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 27% | 27% | 26.60% |
| FII | 24.70% | 25.30% | 25.80% |
| DII | 38.80% | 37.80% | 37.20% |
| Public | 10% | 10% | 10% |
About Dr. Reddy’s Lab
Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY) is a global pharmaceutical company offering APIs, generics, biosimilars and OTC products, with strong presence across major markets and a growing portfolio in oncology and immunology.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
A: Dr. Reddy’s Laboratories Ltd share price is rising as the company receives European Commission approval for its biosimilar AVT03.
A: Dr. Reddy’s Laboratories Ltd has a market capitalization based on its latest trading data published on the exchange.
A: Dr. Reddy’s Laboratories Ltd stock recorded a 52-week high of ₹1,404.60 and a 52-week low of ₹1,025.90.
